Press "Enter" to skip to content

FDA panel votes unanimously in favor of Horizon’s thyroid eye disease drug

Independent advisers to the U.S. Food and Drug Administration on Friday voted unanimously in favor of Horizon Therapeutics Plc’s experimental treatment for active thyroid eye disease, taking the drug closer towards potential approval.

Original source: